KEGG   DISEASE: Irritable bowel syndromeHelp
Entry
H01615                      Disease                                

Name
Irritable bowel syndrome
Description
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.
Category
Digestive system disease
Brite
Human diseases [BR:br08402]
 Digestive system diseases
  Gastrointestinal diseases
   H01615  Irritable bowel syndrome
Human diseases in ICD-11 classification [BR:br08403]
 13 Diseases of the digestive system
  Functional gastrointestinal disorders
   DD91  Irritable bowel syndrome or certain specified functional bowel disorders
    H01615  Irritable bowel syndrome
BRITE hierarchy
Gene
GUCY2C [HSA:2984] [KO:K12320]
Drug
Dicyclomine hydrochloride [DR:D00717]
Alosetron hydrochloride [DR:D02829]
Hyoscyamine sulfate [DR:D00719]
Chlordiazepoxide hydrochloride and clidinium bromide [DR:D10247]
Lubiprostone [DR:D04790]
Linaclotide [DR:D09355]
Plecanatide [DR:D09948]
Eluxadoline [DR:D10403]
Tenapanor hydrochloride [DR:D11653]
Other DBs
ICD-11: DD91.0
ICD-10: K58
MeSH: D043183
OMIM: 614616
Reference
  Authors
Saito YA
  Title
The role of genetics in IBS.
  Journal
Gastroenterol Clin North Am 40:45-67 (2011)
DOI:10.1016/j.gtc.2010.12.011
Reference
  Authors
Shah SL, Lacy BE
  Title
Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence.
  Journal
Curr Gastroenterol Rep 18:41 (2016)
DOI:10.1007/s11894-016-0517-x
Reference
  Authors
von Volkmann HL, Nylund K, Tronstad RR, Hovdenak N, Hausken T, Fiskerstrand T, Gilja OH
  Title
An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.
  Journal
Scand J Gastroenterol 1-8 (2016)
DOI:10.1080/00365521.2016.1200139
Reference
PMID:11488427 (drug)
  Authors
Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K
  Title
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
  Journal
Jpn J Pharmacol 86:281-8 (2001)
DOI:10.1254/jjp.86.281
Reference
PMID:22837880 (drug)
  Authors
Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T
  Title
Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.
  Journal
J Neurogastroenterol Motil 18:317-23 (2012)
DOI:10.5056/jnm.2012.18.3.317
LinkDB All DBs

» Japanese version

DBGET integrated database retrieval system